knowledge -WSS

knowledge

author：comprehensive 2025-09-27 12:43:14 - browse：55

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Christmas in the PICU brings some surprising joy

WSS

How clinical AI models' predictive power can degrade over time

Wellcome Trust names Røttingen as its new CEO

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Researchers CRISPR chickens in bid to protect them from bird flu

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Readout LOUD podcast: Merger Mondays, Ozempic panic

knowledge

knowledge

focus

Medicare proposal to cover medical devices draws a mixed reaction

Violet CEO on training clinicians to promote more inclusive care

As demand for Covid shots wanes, Moderna seeks its next success

Peter Marks talks Operation Warp Speed for Rare Diseases

Peter Hotez and the public health issue of online harassment

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Jerome Adams on the need for new antivirals for Covid

Massive project maps cells in human brain in unprecedented detail

What does generative AI mean for health care? We asked experts

Bristol Myers buys into radiopharmaceuticals with RayzeBio

hotspot

Grail spinoff by Illumina should end disastrous merger attempt

Carvykti CAR

Peter Marks talks Operation Warp Speed for Rare Diseases

In Spain, a hospital brews its own CAR

What the Wegovy shortage looks like for doctors — and for patients

Why health records don't always know when patients are dead

leisure time

hotspot

leisure time

focus